Table 2.
Clinical Characteristics
| CU Boulder | UCLA | All | |
|---|---|---|---|
| n = 264 | n = 155 | n = 419 | |
| % | % | % | |
| Mood Disorders | |||
| Unipolar Disorders | |||
| Major Depressive Disorder | 21.40% | 23.46% | 22.16% |
| Persistent Depressive Disorder | 5.90% | 22.84% | 12.17% |
| Subclinical Depressive Disorder | 12.55% | 4.32% | 9.51% |
| Bipolar Disorders | |||
| Bipolar I Disorder | 1.85% | 4.32% | 2.76% |
| Bipolar II Disorder | 2.58% | 3.09% | 2.77% |
| Bipolar Disorder Not Otherwise Specified | 1.11% | 1.85% | 1.38% |
| Subthreshold Bipolar Disorder | 1.48% | 0.62% | 1.16% |
| Other Mood Disorder Not Otherwise Specified | 5.90% | 6.79% | 6.23% |
| Schizoaffective Disorder | 0.00% | 1.23% | 0.46% |
| No Mood Disorders | 47.23% | 31.48% | 41.40% |
| Secondary Disorders | |||
| Anxiety Disorders | 14.77% | 27.10% | 19.33% |
| Substance Use Disorders | |||
| Mild | 5.30% | 12.26% | 7.87% |
| Moderate or Severe | 1.14% | 8.39% | 3.82% |
| Eating Disorders | 1.51% | 5.16% | 2.86% |
| Trauma and Stress-Related Disorders (Lifetime) | 6.43% | 14.84% | 9.54% |
| Attention Deficit Hyperactivity Disorder | 8.33% | 14.19% | 10.50% |
| Unknown | 3.03% | 7.10% | 4.54% |
| Medications | |||
| Anticonvulsant | 1.14% | 8.39% | 3.82% |
| Anxiolytic (not within 48 hours of session) | 0.76% | 1.93% | 1.19% |
| Atypical antipsychotic | 0.38% | 5.16% | 2.15% |
| Benzodiazepine (not within 48 hours of session) | 0.76% | 3.22% | 1.67% |
| Lithium | 0.00% | 1.93% | 0.71% |
| Beta-blockers (not within 48 hours of session) | 1.51% | 1.93% | 1.67% |
| Norepinephrine-dopamine reuptake inhibitor | 0.38% | 7.74% | 3.10% |
| Selective serotonin-norepinephrine reuptake inhibitor | 0.76% | 3.87% | 1.91% |
| Serotonin antagonist and reuptake inhibitor | 1.14% | 2.58% | 1.67% |
| Selective serotonin reuptake inhibitor | 8.71% | 17.42% | 11.93% |
| Stimulant (not within 48 hours of session) | 4.54% | 5.16% | 4.77% |
| Tetracyclics | 0.00% | 0.38% | 0.14% |
| Any psychoactive medication | 20.07% | 32.26% | 24.58% |
Note. Reported are lifetime mood diagnoses. Current mood symptom severity is reflected in primary dimensional measures reported in main text. Comorbid psychiatric disorders secondary to current mood disorders were permitted in this study and are reported above, based on standard DSM5 criteria and with extended reporting on Substance Use Disorders and Eating Disorders (i.e., remitted but recent diagnoses – past one year for SUDs, past two years for EDs – are reported for those categories) and Trauma and Stress Related Disorders (lifetime history). Current use of psychoactive medications is reported, and eligibility criteria required that participants were on a stable medication and dose (no changes in past six weeks) and abstained from use of stimulant, beta-blocker, anxiolytic, or benzodiazepine medication for 48+ hours prior to the research session. Analyses were repeated excluding individuals with secondary disorders or for whom secondary disorder data was incomplete/unknown, or covarying use of psychoactive medications, but these exclusions did not influence the nature or significance of effects therefore the full sample was retained for analyses.